Hou et al. (73) revealed that an interleukin-1 receptor-associated kinase (IRAK) inhibitor lowered inflammatory factor production by downregulating TLR4 receptor expression, thereby reducing the severity of NEC-induced intestinal inflammation. The gene discussed is IRAK1; the disease is necrotizing enterocolitis.